Composition for improving osteoporosis and preparation method and applications thereof

A technology of osteoporosis and composition, which is applied in the field of composition for improving osteoporosis, can solve the problems of ineffective improvement of osteoporosis, no obvious promotion effect of bone formation, and toxic and side effects, so as to accelerate bone marrow cell hematopoiesis, The effect of promoting and improving osteoporosis

Inactive Publication Date: 2019-04-12
HOBOOMLIFE BIO TECH SHENZHEN CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the traditional method of preventing and treating osteoporosis is to take calcium carbonate tablets orally. Supplementing calcium can indeed alleviate osteoporosis, but this method has certain defects. For example, taking inorganic calcium will neutralize gastric acid and cause belching, constipation and other adverse effects. Induction, and the improvement effect on osteoporosis is not obvious, long-term use has no obvious promotion effect on bone resorption and bone formation
There are also some Chinese patent medicine products on the market, but most of them have problems such as poor effect or toxic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] The present embodiment provides a composition for improving osteoporosis, which includes NMN, NADPH, ginsenoside PPD, ginsenoside Rh2, chondroitin sulfate and active ingredients, the active ingredients are taurine, phosphatidylserine, ursine At least one of oxycholic acid, sialic acid, s-adenosylmethionine, γ-aminobutyric acid, astaxanthin, and pyroglutamate.

[0026] Wherein, the active ingredient may be one of taurine, phosphatidylserine, ursodeoxycholic acid, bird's nest acid, s-adenosylmethionine, γ-aminobutyric acid, astaxanthin, and pyroglutamate. It can also be that the active ingredients include at least taurine, phosphatidylserine, ursodeoxycholic acid, sialic acid, s-adenosylmethionine, γ-aminobutyric acid, astaxanthin, pyroglutamic acid several kinds of acid esters; preferably, the active ingredients include at least taurine, phosphatidylserine, ursodeoxycholic acid, sialic acid, s-adenosylmethionine, γ-aminobutyric acid, astaxanthin, At least five of pyrogl...

Embodiment 2

[0034] This embodiment provides a composition for improving osteoporosis. In parts by weight, the composition includes: 10 parts of NMN, 1 part of NADPH, 10 parts of ginsenoside PPD, 21 parts of ginsenoside Rh, 10 parts of chondroitin sulfate, 6 parts of deoxycholic acid, 4 parts of s-adenosylmethionine. The composition was prepared using the method described in Example 1.

[0035] This embodiment also provides a kind of pharmaceutical preparation, described pharmaceutical preparation comprises described composition and auxiliary material, and the weight portion of described auxiliary material is 10 parts, and described auxiliary material comprises magnesium hydroxide, calcium sulfate, microcrystalline cellulose, and above-mentioned auxiliary material The mass ratio of the components is 1:2:1. In this embodiment, the pharmaceutical preparation is a granule, which is prepared by the following method: pass the dried composition and auxiliary materials through a 60-mesh sieve, s...

Embodiment 3

[0037] The present embodiment provides a composition for improving osteoporosis. In parts by weight, the composition includes: 2 parts of NMN, 3 parts of NADPH, 3 parts of ginsenoside PPD, 3 parts of ginsenoside Rh2, and 2 parts of chondroitin sulfate , 2 parts of active ingredients, the active ingredients include taurine, s-adenosylmethionine, γ-aminobutyric acid, astaxanthin, pyroglutamate, the mass ratio of each component in the active ingredients is 1 :1:2:1:1. The composition was prepared using the method described in Example 1.

[0038] This embodiment also provides a kind of pharmaceutical preparation, described pharmaceutical preparation comprises described composition and adjuvant, and the weight portion of described adjuvant is 8 parts, and described adjuvant comprises xylitol, sorbitan fatty acid ester, stearin magnesium hydroxide, croscarmellose sodium, magnesium hydroxide, pregelatinized starch, the mass ratio of the above-mentioned auxiliary material components ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of health care products, and discloses a composition for improving osteoporosis and a preparation method and applications thereof. The composition comprises NMN, NADPH, ginsenoside PPD, ginsenoside Rh2, chondroitin sulfate and active ingredients. The active ingredients include at least one of phosphatidylserine, ursodeoxycholic acid, sialic acid, s-adenosylmethionine, gamma-aminobutyric acid, astaxanthin and pyroglutamic acid ester. The above-mentioned components work synergistically to greatly promote the cell oxygen supply and the calcium absorption, and can accelerate the hematopoiesis of bone marrow cells. The above prescription is simple in components, and has obvious effects on improving osteoporosis. According to clinical observation, thetreatment rate can reach 97% or above. The original medicinal materials of the components of the composition are botanical herbs, and provide a guarantee for the drug safety.

Description

technical field [0001] The invention belongs to the technical field of health care products, and in particular relates to a composition containing NMN for improving osteoporosis, a preparation, a preparation method and application thereof. Background technique [0002] Osteoporosis (OP) is a progressive disease characterized by decreased bone mass, decreased bone strength, increased bone fragility, degenerative changes in microstructure, and increased risk of fracture. Osteoporosis has become a global health problem. About 200 million people in the world suffer from osteoporosis, and the incidence of osteoporosis ranks seventh among chronic diseases. [0003] Traditional Chinese medicine research believes that the cause of osteoporosis is mainly related to liver, spleen and kidney deficiency and blood stasis, among which liver and kidney deficiency is the main pathogenesis of osteoporosis, spleen deficiency is also an important pathogenesis, and blood stasis is the promoting...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/185A61K31/685A61K31/575A61K31/7076A61K31/197A61K31/122A61K31/4015A61K31/7024A61K31/704A61K31/737A61K31/706A23L33/175A23L33/10A61P19/10
CPCA23L33/10A23L33/175A23V2002/00A61K31/122A61K31/185A61K31/197A61K31/4015A61K31/575A61K31/685A61K31/7024A61K31/704A61K31/706A61K31/7076A61K31/737A61P19/10A61K2300/00A23V2200/306
Inventor 陈建生李峰张波段志刚陈晓娟胡欢
Owner HOBOOMLIFE BIO TECH SHENZHEN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap